EGFR and non-small cell lung carcinoma: The median overall survival in our cohort was 36.2 months, comparable to a recent report of 37.0 months in advanced EGFR-mutant NSCLC patients receiving gefitinib, erlotinib, or afatinib [19], as well as another report of 36.7 months in those treated with afatinib alone in our institution [30].